Introduction and Objectives: To describe the use of C3G in 565 healthcare facilities. Materials and methods: A cohort of volunteer healthcare facilities that participated in the ATB-RAISIN Network surveillance program each year from 2008 to 2012 (14 university hospitals, 178 general hospitals, 165 community hospitals, 8 cancer care centers, 5 specialized hospitals, 113 specialized care facilities, 35 long-term care facilities, 5 long-term care homes, and 43 psychiatric facilities). Annual consumption compiled in terms of defined daily doses (DDD, as defined by the WHO) per 1,000 hospital days (HD) for the healthcare system as a whole and by sector of activity. Results: C3G consumption in the 565 healthcare facilities increased by 33%, from 26 to 34 DDD/1,000 HD between 2008 and 2012 (an increase regardless of the type of healthcare facility). Ceftriaxone was the most commonly used C3G (71% of injectable C3Gs and 82% of injectable C3Gs without activity against P. aeruginosa in 2012), and the one whose consumption had increased the most: from 14.3 DDD/1,000 population in 2008 to 21.3 in 2012 (+48%). Cefotaxime consumption remained stable at 4.5 to 4.7 DDD/1,000 population over the same period. In 2012, ceftriaxone consumption varied by region from 12 to 30 DDD/1,000 hospital days. The share of ceftriaxone in total consumption ranged from 0 to 25% in medicine, from 0 to 15% in surgery, and from 0 to 20% in intensive care. Conclusion: The ATB-RAISIN surveillance system reveals a concerning increase in the consumption of C3G antibiotics, particularly ceftriaxone, consistent with national surveys on the prevalence of nosocomial infections and antimicrobial treatments. The variations observed between comparable clinical sectors suggest opportunities for improvement. Given the ecological impact of this class of antibiotics on the gut microbiota, there is an urgent need to better understand the factors associated with their prescription in order to implement measures ensuring their appropriate use. (R.A.)